EVOQTrading & Distributors
Evoq Remedies Ltd — Profit & Loss Statement
₹2.30
+0.80%
Evoq Remedies Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.31 | 0.26 | 0.29 | 0.25 | — |
| Normalized EBITDA | 0.18 Cr | 0.62 Cr | -3.73 Cr | 1.46 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Reconciled Depreciation | 0.05 Cr | 73000.00 | 39000.00 | 0.00 | — |
| Reconciled Cost Of Revenue | 13.08 Cr | 1.56 Cr | 19.33 Cr | 13.77 Cr | — |
| EBITDA | 0.18 Cr | 0.62 Cr | -3.73 Cr | 1.46 Cr | — |
| EBIT | 0.13 Cr | 0.61 Cr | -3.74 Cr | 1.46 Cr | — |
| Net Interest Income | 0.00 | 0.00 | -13000.00 | -46000.00 | — |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Normalized Income | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Total Expenses | 14.04 Cr | 5.70 Cr | 24.13 Cr | 15.32 Cr | — |
| Diluted NI Availto Com Stockholders | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Net Income Common Stockholders | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Net Income Including Noncontrolling Interests | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 0.09 Cr | 0.45 Cr | 1.62 Cr | 1.09 Cr | — |
| Tax Provision | 0.04 Cr | 0.16 Cr | 0.67 Cr | 0.37 Cr | — |
| Pretax Income | 0.13 Cr | 0.61 Cr | 2.28 Cr | 1.46 Cr | — |
| Other Non Operating Income Expenses | 2.41 Cr | 2.26 Cr | 6.02 Cr | — | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | 0.00 | 0.00 | -13000.00 | -46000.00 | — |
| Interest Expense Non Operating | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Operating Income | -2.29 Cr | -1.65 Cr | -3.74 Cr | 1.46 Cr | — |
| Operating Expense | 0.96 Cr | 4.14 Cr | 4.80 Cr | 1.55 Cr | — |
| Other Operating Expenses | 0.84 Cr | 4.06 Cr | 0.28 Cr | 0.18 Cr | — |
| Depreciation And Amortization In Income Statement | 0.05 Cr | 73000.00 | 39000.00 | 0.00 | — |
| Depreciation Income Statement | 0.05 Cr | 73000.00 | 39000.00 | 0.00 | — |
| Gross Profit | -1.32 Cr | 2.50 Cr | 1.06 Cr | 3.01 Cr | — |
| Cost Of Revenue | 13.08 Cr | 1.56 Cr | 19.33 Cr | 13.77 Cr | — |
| Total Revenue | 11.76 Cr | 4.05 Cr | 20.39 Cr | 16.78 Cr | — |
| Operating Revenue | 11.76 Cr | 4.05 Cr | 20.39 Cr | 16.78 Cr | — |
| Rent Expense Supplemental | — | 0.00 | 0.01 Cr | 84000.00 | 0.09 Cr |
| Diluted Average Shares | — | 1.37 Cr | 1.36 Cr | 1.56 Cr | 1.36 Cr |
| Basic Average Shares | — | 1.37 Cr | 1.36 Cr | 1.56 Cr | 0.10 Cr |
| Diluted EPS | — | 0.33 | 1.19 | 0.70 | 7.15 |
| Basic EPS | — | 0.33 | 1.19 | 0.70 | 7.15 |
| Write Off | — | 0.06 Cr | 0.00 | 0.00 | 0.00 |
| Total Other Finance Cost | — | 1000.00 | 13000.00 | 46000.00 | 1165.00 |
| Selling General And Administration | — | 3.78 Cr | 4.30 Cr | 1.18 Cr | 0.96 Cr |
| Selling And Marketing Expense | — | 3.71 Cr | 4.14 Cr | 1.13 Cr | 0.95 Cr |
| General And Administrative Expense | — | 0.06 Cr | 0.16 Cr | 0.05 Cr | 35000.00 |
| Rent And Landing Fees | — | 0.00 | 0.01 Cr | 84000.00 | 0.09 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Evoq Remedies Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.